ARMATA PHARMACEUTICALS INC
ARMPNYSE AMERICANTrading Snapshot
- Day Range
- $4.23 – $4.29
- 52-Week Range
- $2.36 – $16.34
- Volume
- $2.62B
- Avg Volume
- $2.11B
- Shares Outstanding
- 36.7M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $789,000
- P/E Ratio
- —
- P/S Ratio
- 32.4x
- EPS (TTM)
- $-7.76
- Dividend Yield
- —
Why Investors Own ARMP
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ARMATA PHARMACEUTICALS INC
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva's strategic investments valued at $773 million carry a meaningful impairment risk while providing upside optionality. Learn more about INVA stock here.
Why Is Armata Pharma Stock Gaining Monday?
ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.
Armata Pharma Promotes David House To CFO
Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Officer. Mr. House has served as the Company's Senior Vice President, Finance and Principal Financial Officer since
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything
Armata Pharmaceuticals is a Hold until Phase 3 AP-SA02 data, given a funding-dependent profile and limited margin for error. Read more on ARMP stock here.
Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patientsLOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP)